Yuandong Bioscience: Completion of First Subject Dosage in Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection

Yuandong Bio announced that the Phase I clinical trial of EP-0210 monoclonal antibody injection, a type 1 biopharmaceutical developed by its wholly-owned subsidiary Chengdu Yulo Bio-Technology Co., Ltd. for the treatment of inflammatory bowel disease, has been completed with the first subject dosed. This drug is a humanized IgG1 monoclonal antibody drug targeting human tumor necrosis factor-like ligand 1A, which surpasses the foreign competitor RVT-3101 in terms of target activity and in vivo efficacy. Currently, there are no drugs targeting the same target on the market globally, and domestically, the fastest progress in the development of drugs targeting the same target is by companies such as MSD, Sanofi, Roche/Pfizer, with their drugs all in Phase III clinical trials. Yuandong Bio stated that they will accelerate the clinical trials of EP-0210 monoclonal antibody injection and fulfill their disclosure obligations in a timely manner.